Can reversibility determine clinical course in patients with COPD?

Dmytriiev, Kostiantyn; Mostovoy, Yuriy; Slepchenko, Nataliia; Tsymbaliuk, Nataliia; Sidorov, Andrii; Dmytriiev, Dmytro; Shostatska, Mariia

doi:10.1183/13993003.congress-2020.1041

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different studies have demonstrated a difference in response to beta-2 agonists and inhaled corticosteroids depending on the ADRB2 polymorphism [7,9], that can directly impact a clinical course of COPD [3].…”

Section: Introductionmentioning

confidence: 99%

Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene

Mostovoy

Dmytriiev

Slepchenko

2021

Biomed. and Biosoc. Anthrop.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a widely spread disease, that can be prevented and treated. As it was mentioned in the GOLD guidelines, genetic factors have a prominent impact on the development of COPD. A great amount of different genes is involved into the development of COPD. They influence processes of inflammation, fibrosis and regulation of airways reactivity. Polymorphism of ADRB2 gene is of a particular interest as it is associated with the development of COPD and response to beta-2 agonists, which are the main drugs used in the treatment of COPD. The aim of our study was to investigate an impact of the polymorphism of ADRB2 gene on the clinical course of COPD. We collected source data, medical history in all patients in order to assess smoking status and smoking experience, clinical group of COPD according to GOLD classification, total amount of exacerbations, exacerbations treated in in-patient and out-patient conditions, data about use of antibiotics, glucocorticosteroids and methylxanthines. Blood was collected in all patients for the genetic analysis of ADRB2 gene polymorphism. Among COPD patients 65 (65 %) had changes in ADRB2 gene. 26 patients (26 %) had mutation and 39 patients (39 %) had polymorphism of ADRB2 gene, which indicate possible relation of ADRB2 gene with the COPD development. Patients of group 1, C79C allele carriers, had milder COPD course, which presented with the significant difference in the of GOLD D patients in this group (17.14±7.13 %) and group 2, C79G allele carriers, (58.97±8.15 %) and group 3, G79G allele carriers, (34.61±9.59 %). Group 1 patients had lower amount of exacerbations (2.543±0.281) when compared to group 3 (2.963±0.273), and lower amount of hospital admissions (1.031±0.154) when compared to group 2 (1.332±0.167). Group 1 patients also used less antibiotics then other groups. So, ADRB2 gene polymorphism in C79G positions is a prognostic factor of the severity of COPD course. It is associated with the greater amount of exacerbations and hospitalizations and also greater antibiotic use.

show abstract

Section: Introductionmentioning

confidence: 99%

Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene

Mostovoy

Dmytriiev

Slepchenko

2021

Biomed. and Biosoc. Anthrop.

View full text Add to dashboard Cite

show abstract

Efficacy of Combination of Tiotropium/Olodaterol in Patients With Copd in Real Clinical Practice

et al. 2022

View full text Add to dashboard Cite

The aim: Show the efficacy of the Tiotropium / olodaterol combination in real clinical practice. Materials and methods: 100 patients with the diagnosis of COPD were included onto the study during the period of 2019-2020, an average age was 64.09±1.94 years, 66 were men (66 %) and 34 were women (34 %). There were 68 % of smokers with the average smoking experience of 24.44±4.84 pack-years. Average COPD duration was 9.35±2.42 years. There were 3 visits in the study – visit 1 (baseline), visit 2 (4-6 weeks) visit 3 (1 year). Source documentation was assessed at visit 1 and visit 3 for amount of exacerbations, antibiotic, glucocorticosteroid, methylxanthines use; mMRC and CAT were assessed at all visits. Results: Combined therapy with tiotropium/olodaterol improves clinical course of COPD, which is characterized by the significant decreased of the amount of exacerbations (2.63±0.29 to 1.63±0.21) and hospital admissions (1.2±0.2 tо 0.37±0.11). Improvement of symptoms and amount of exacerbation leads to much less use of antibiotics and glucocorticosteroids. A part of patients that used antibiotics decreased from 86±6.9 % to 67±9.3 %, amount of antibiotic courses from 1.37±0.17 tо 0.88±0.15, duration of treatment with antibiotics from 10.85±1.53 to 6.12±1.17 days. Part of the patients that used glucocorticosteroids decreased from 50±9.9 % tо 30±9.1 %, duration of treatment with antibiotics reduced from 3.97±1.06 tо 1.86±0.91 days. There also was a tendency towards a lesser used of methylxanthines. Combined therapy with tiotropium/olodaterol significantly decreased symptoms of COPD according to the mMRC (2.3±0.14 to 1.87±0.15) and САТ (23.28±1.71 to 15.77±1.58). Conclusions: Tiotropium/olodaterol combination showed its efficacy in real clinical practice. There was significant reduction in amount of exacerbation and antibiotic, gluco¬corticosteroid use during the study, which was also accompanied by the reduction is symptoms.

show abstract

Can reversibility determine clinical course in patients with COPD?

Cited by 2 publications

References 0 publications

Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene

Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene

Efficacy of Combination of Tiotropium/Olodaterol in Patients With Copd in Real Clinical Practice

Contact Info

Product

Resources

About